Peptide reference
Lanreotide
Somatuline ·Somatuline Depot ·Somatuline Autogel ·BIM 23014 ·Angiopeptin
What cited sources report about Lanreotide
Lanreotide is a synthetic cyclic octapeptide analogue of somatostatin developed by Ipsen and marketed as Somatuline Depot (US) and Somatuline Autogel (EU/elsewhere). It is FDA-approved for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome, and is administered as a long-acting deep subcutaneous injection. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
FDA DailyMed — Somatuline Depot prescribing information
The current US prescribing information lists three approved indications for Somatuline Depot: long-term treatment of acromegaly in patients with inadequate response to or contraindications for surgery and radiotherapy; treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival; and treatment of carcinoid syndrome to reduce the frequency of short-acting somatostatin analog rescue therapy. The label documents a recommended starting dose of 90-120 mg by deep subcutaneous injection every 4 weeks.
SOMATULINE DEPOT is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
Caplin et al. (2014) — New England Journal of Medicine (CLARINET)
The CLARINET trial was a randomized, double-blind, placebo-controlled phase 3 study of 204 patients with non-functioning, well- or moderately-differentiated, locally advanced or metastatic enteropancreatic neuroendocrine tumors. Median progression-free survival was not reached for lanreotide versus 18.0 months for placebo, with a hazard ratio of 0.47 (95% CI 0.30-0.73). The authors concluded that lanreotide was associated with prolonged progression-free survival in this population.
Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%).
Castinetti and Ioachimescu (2026) — Journal of Clinical Endocrinology and Metabolism
A 2026 narrative review surveyed the current pharmacologic landscape for acromegaly, including transsphenoidal surgery as first-line management and the role of long-acting somatostatin receptor ligands — lanreotide and octreotide — as first-line medical therapy when surgery is incomplete or contraindicated. The authors described the comparative efficacy data for somatostatin ligands, dopamine agonists, GH receptor antagonists, and combination regimens.
PubChem CID 71349 — National Center for Biotechnology Information
The PubChem compound record for lanreotide lists the cyclic octapeptide D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, molecular formula C54H69N11O10S2, and molecular weight 1096.3 g/mol. The record aggregates development names (BIM 23014, angiopeptin) and links to the supporting chemical and patent literature.
Coverage notes
Lanreotide is a long-established somatostatin analogue with mature evidence in acromegaly and GEP-NETs and a well-characterized depot pharmacokinetic profile. The CLARINET trial (Caplin 2014) is the pivotal randomized evidence supporting the GEP-NET indication. This page reflects FDA labeling and EMA product information current as of the cited sources.